Mechanism of EGR2 in Allergic Rhinitis

Zu-xia Ma

Status and phase: Invitation-only; Phase 1

Conditions: Rhinitis, Allergic

Treatments: Genetic: EGR2

Study type: Interventional

Funder types: Other

Identifiers

NCT05724290

[2018]1182

Details and patient eligibility

About

EGR2 may be a target for the treatment of nasal polyps.

Full description

There is much debate about the etiology of nasal polyps, so the pathogenesis of nasal polyps still needs to be clarified. Surgery for noninflammatory nasal polyps may be better control, but surgery is not effective for recurrent sinusitis and nasal polyps. Therefore, more research is needed to determine the best targeted therapy for nasal polyps. We found that EGR2 expression was upregulated in CRSwNP patients with allergic rhinitis.In addition, the expression of EGR2 in CRSwNP mucosa was significantly higher than that in the control group, and the expression of EGR2 in CRSwNP with allergic rhinitis was higher than that in CRSwNP without allergic rhinitis. EGR2 may be involved in the pathogenesis of nasal polyps, and may also be related to the severity and recurrence of nasal polyps. EGR2 may be a target for the treatment of nasal polyps.

Enrollment: 3 estimated patients

Sex: All

Ages: 16 to 76 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

All patients were stopped by systemic or topical corticosteroid treatment at least one month before the study.

Exclusion criteria

Patients had NPs accompanied by choanal polyps, fungal nasal sinusitis, cystic fibrosis, acute upper airway upper infection or other systemic diseases.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

3 participants in 2 patient groups

immunohistochemistry

Experimental group

Description:

Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry

Treatment:

Genetic: EGR2

WestBlot

Experimental group

Description:

Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.

Treatment:

Genetic: EGR2